K-PAX Pharmaceuticals Develops Chronic Fatigue Syndrome Treatment

A pharmaceutical company based out of Mill Valley has developed a treatment for chronic fatigue sydrome. K-PAX, headed by Dr. Jon Kaiser, believes that its treatment will help thousands with the disease return to functional lives. The treatment involves a combination of K-PAX nutritional supplements and a small dose of Ritalin. Chronic fatigue sydrome has remained a long time medical mystery, and researchers are still unaware of the cause of the condition. The disease is not completely understood in the medical community. The CDC lists symptoms as muscle pain, impaired memory or mental concentration, insomnia, and post-exertion malaise lasting more than 24 hours.

Dr. Jon Kaiser admits that the disease has been neglected. He also stated that clincial studies on K-PAX treatments have helped patients find relief from some of their life altering symptoms. “There are very few pharmaceutical companies working on developing a treatment for this neglected disease,” said Kaiser. “Why is this? Because it has been very difficult to understand and no clearly definable pharmaceutical target has been identified.”

Kaiser also addressed the results of K-PAX clinical trials. “More than two-thirds of them experienced clinically significant improvement in both fatigue and concentration symptoms. One woman had been out of work for six years due to her symptoms and went back to work six weeks after starting this treatment.”

Although the K-PAX clinical trials results are promising, the study still has to be replicated on a larger scale. K-PAX plans to conduct further research at Stanford University’s School of Medicine in a study with 120 people.